The Journal of Clinical Endocrinology & Metabolism · 2009 · 72 citations · 32 references
MedicineEndocrinologyPediatricsPediatric EndocrinologyPediatric PharmacotherapyPediatric TherapeuticsChild GrowthGrowth AssessmentGrowth DisordersPediatric Clinical TrialsPediatric Endocrine DisordersPediatric GrowthBody Weight - Based DosingGrowth Outcomes In ChildrenGrowth Velocity AssessmentInsulin-like Growth Factor 1 DeficiencyInsulin-like Growth Factor DeficiencyInsulin-like Growth Factor-1Open-label TrialsWeight-based Infusion Dosing
CONTEXT: Short stature in children may be associated with low IGF-I despite normal stimulated GH levels and without other causes. OBJECTIVE: Our objective was to assess the safety and efficacy of recombinant human IGF-I (rhIGF-I) in short children with low IGF-I levels. DESIGN: This was a 1-yr, randomized, open-label trial (MS301). SETTING: The study was conducted at 30 U.S. pediatric endocrinology clinics. SUBJECTS: A total of 136 short, prepubertal subjects with low IGF-I (height and IGF-I sd scores <-2, stimulated GH > or =7 ng/ml); 124 completed the study, and six withdrew for adverse events and six for other reasons. INTERVENTION: rhIGF-I was administered sc, twice daily using weight-based dosing (40, 80, or 120 microg/kg; n = 111) or subjects were observed (n = 25). MAIN OUTCOME MEASURES: First-year height velocity (centimeters per year, cm/yr), height sd score, IGF-I, and adverse events were prespecified outcomes. RESULTS: First-year height velocities for subjects completing the trial were increased for the 80- and 120-microg/kg twice-daily vs. the untreated group (7.0 +/- 1.0, 7.9 +/- 1.4, and 5.2 +/- 1.0 cm/yr, respectively; all P < 0.0001) and for the 120- vs. 80-microg/kg group (P = 0.0002) and were inversely related to age. They were not predicted by GH stimulation or IGF-I generation test results and were not correlated with IGF-I antibody status. The most commonly reported adverse events of special interest during treatment were headache (38% of subjects), vomiting (25%), and hypoglycemia (14%). CONCLUSIONS: rhIGF-I treatment was associated with age- and dose-dependent increases in first-year height velocity. Adverse events during treatment were less common than in previous studies and were generally transient, easily managed, and without known sequelae.
32
Katie A. Woods, Cecilia Camacho‐Hübner, Martin O. Savage et al. · New England Journal of Medicine · 1996 · 1.1K citations · Full text
Paul J. Godowski, David W. M. Leung, Lillian R. Meacham et al. · Proceedings of the National Academy of Sciences · 1989 · 603 citations
Growth Hormone Insensitivity Associated with a<i>STAT5b</i>Mutation
Eric M. Kofoed, Vivian Hwa, Brian M. Little et al. · New England Journal of Medicine · 2003 · 524 citations · Full text
Steven D. Chernausek, Philippe Backeljauw, James W. Frane et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 246 citations · Full text
Medicine, Endocrinology, Pediatrics +16
Head Circumference Reference Data: Birth to 18 Years
Alex F. Roche, Debabrata Mukherjee, Shumei Guo et al. · PEDIATRICS · 1987 · 238 citations